South Australian Neonatal Medication Guidelines

thyroxine 50microgram tablet © Department of Health, Government of South Australia. All rights reserved

Note

This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient's medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary.
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Synonyms

T4, levothyroxine

Dose and Indications

Congenital hypothyroidism

Oral

Up to 10microgram/kg once a day, rounded to the nearest 12.5 microgram.

Preparation and Administration

Oral

Thyroxine tablets are very soluble in water.

Add one 50microgram tablet to the barrel of a syringe and draw up sterile water to a volume of 1mL. The resulting solution contains 50microgram/mL thyroxine.

| Dose | 12.5microgram | 25microgram | 50microgram |
|--------|---------------|-------------|-------------|
| Volume | 0.25mL | 0.5mL | 1mL |

Use solution immediately and discard any remaining solution.

ISBN number: 978-1-74243-544-2

Endorsed by: South Australian Maternal & Neonatal Clinical Network

Last Revised: 18/07/2013

Contact: South Australian Neonatal Medication Guidelines Workgroup at:

NeoMed@health.sa.gov.au



Page 1 of 2

thyroxine 50microgram tablet

Adverse Effects

Symptoms of hyperthyroidism, eg tachycardia, arrhythmia, tremors or jitters, insomnia, flushing, sweating, diarrhoea and excessive weight loss.

Monitoring

- > Aim to closely monitor thyroid function using free T4 and TSH at 2 weeks after starting the medication then 2-3 monthly during the first 4 years.
- > It is recommended to re-check thyroid function 2-3 weeks after dose changes.
- > Adjust dose to maintain serum thyroxine in the upper half of the normal range and serum TSH level in the normal range.

Practice Points

- > Avoid milk/food within 30minutes of dose
- > For appropriate patients, dose can be rounded off to the nearest 25mg (half a tablet) instead of 12.5mg, and given on alternate days
- > Thyroxine has a long half-life and so doses may be given every alternate day if needed. This may work out easier to administer as the dose can be rounded to the nearest tablet strength.
- Oral dosing produces effect within 3 to 5 days of therapy. The clinical effect will continue for 1 week following discontinuation of therapy.
- > Dose should be repeated if baby vomits or regurgitates within 15 minutes.

Version control and change history

PDS reference: OCE use only

| Version | Date from | Date to | Amendment |
|---------|-----------|---------|------------------|
| 1.0 | July 2013 | current | Original version |
| | | | |
| | | | |
| | | | |

ISBN number: 978-1-74243-544-2

Endorsed by: South Australian Maternal & Neonatal Clinical Network

Last Revised: 18/07/2013

Contact: South Australian Neonatal Medication Guidelines Workgroup at:

NeoMed@health.sa.gov.au

